CLAIMS

1. A compound of general formula I



[I]

wherein R_1 represents a substituent selected from the group consisting of halogen, hydroxy, mercapto, trifluoromethyl, amino, (C_1-C_3)alkyl, (C_2-C_3)olefinic group, (C_1-C_3)alkoxy,

(C_1-C_3)alkylthio, (C_1-C_4)alkylamino and cyano;

R_2 represents one or more, same or different substituents selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, (C_1-C_3)alkyl, (C_2-C_3)olefinic group, (C_1-C_3)alkoxy, (C_1-C_3)alkylthio, (C_1-C_4)alkylamino, (C_1-C_3)alkoxycarbonyl, cyano, and nitro;

R_3 represents one or more, same or different substituents selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, cyano, carboxy, carbamoyl, (C_1-C_4)alkyl, (C_2-C_4)olefinic group, (C_1-C_4)alkoxy, (C_1-C_4)alkylthio, and (C_1-C_4)alkoxycarbonyl;

R_4 represents one or more, same or different substituents selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, (C_1-C_3)alkyl, (C_2-C_3)olefinic group, (C_1-C_3)alkoxy, (C_1-C_3)alkylthio, (C_1-C_4)alkylamino, (C_1-C_3)alkoxycarbonyl, cyano, and nitro;

R_5 represents hydrogen, $(C_1\text{-}C_6)$alkyl and $(C_2\text{-}C_6)$olefinic group;

R_6 represents hydrogen, $(C_1\text{-}C_6)$alkyl and $(C_2\text{-}C_6)$olefinic group;

R_7 represents $(C_1\text{-}C_{18})$alkyl, $(C_3\text{-}C_8)$cyclic hydrocarbon group, $(C_2\text{-}C_{18})$olefinic group, heterocyclyl, $(C_2\text{-}C_{18})$alkynyl, $(C_1\text{-}C_{18})$alkyl-heterocyclyl, $(C_1\text{-}C_{18})$alkyl-$(C_3\text{-}C_8)$cyclic hydrocarbon group, $(C_2\text{-}C_{18})$olefinic group-heterocyclyl, $(C_2\text{-}C_{18})$olefinic group-$(C_3\text{-}C_8)$cyclic hydrocarbon group, $(C_2\text{-}C_{18})$alkynyl-heterocyclyl, $(C_2\text{-}C_{18})$alkynyl-$(C_3\text{-}C_8)$cyclic hydrocarbon group; and wherein R_7 may optionally be substituted by one or more substituents represented by R_8;

R_8 represents halogen, hydroxy, mercapto, trifluoromethyl, amino, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $(C_1\text{-}C_6)$alkylthio, $(C_1\text{-}C_6)$alkylamino, $(C_1\text{-}C_6)$alkoxycarbonyl, $(C_1\text{-}C_9)$trialkylammonium in association with a pharmaceutically acceptable anion, $(C_2\text{-}C_{12})$dialkylphosphinoyl, $(C_1\text{-}C_6)$alkyl(hydroxy)phosphinoyl, $(C_2\text{-}C_{12})$dialkylphosphinoyloxy, $(C_1\text{-}C_6)$alkyl(hydroxy)phosphinoyloxy, dihydroxyphosphinoyl, dihydroxyphosphinoyloxy, cyano, azido, nitro, -CHO, -COOH, -$CONH_2$, -CONHR', -CONRR' wherein R and R' represent $(C_1\text{-}C_3)$alkyl or Y-R_9;

Y represents –O-, -S-, -S(O)-, -$S(O)_2$-, -NR_a-, -$NR_aC(O)NR_b$-, -$NR_aC(O)$-, -$C(O)NR_a$-, -C(O)-, -C(O)O-, -OC(O)-, -$NR_aC(O)O$-, -$OC(O)NR_a$-, -$S(O)_2NR_a$-, -$NR_aS(O)_2$-, -OC(O)O- or -$O(CH_2CH_2O)_n$- wherein n is an integer between 1 and 6, and R_a and R_b independently represents hydrogen or $(C_1\text{-}C_3)$alkyl;

R_9 represents $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$olefinic group, $(C_3\text{-}C_6)$cyclic hydrocarbon group, heterocyclyl, $(C_2\text{-}C_6)$alkynyl, $(C_1\text{-}C_6)$alkyl-$(C_3\text{-}C_6)$cyclic hydrocarbon or $(C_1\text{-}C_6)$alkyl-heterocyclyl, and wherein R_9 may optionally be substituted by one or more substituents represented by R_{10};

R_{10} represents halogen, hydroxy, mercapto, trifluoromethyl, amino,

$(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, $(C_1$-$C_6)$alkylthio, $(C_1$-$C_6)$alkylamino or $(C_1$-$C_6)$alkoxycarbonyl;

and pharmaceutically acceptable salts, solvates and hydrates thereof.

2. A compound according to claim 1, wherein R_1 represents fluoro, chloro or bromo, methyl or methoxy

3. A compound according to claim 1 or 2, wherein R_2 represents on or more substituents selected from the list consisting of hydrogen, fluoro, chloro, methyl or methoxy.

4. A compound according to any of claims 1-3, wherein R_2 represents 2-chloro.

5. A compound according to any of claims 1-4, wherein R_3 represents one or more substituents selected from the list consisting of hydrogen, fluoro, chloro, methyl, ethyl, ethenyl or methoxy.

6. A compound according to any of claims 1-5, wherein R_3 represents 2-methyl and 4-fluoro, or 2-methyl and 4-bromo.

7. A compound according to any of claims 1-6, wherein R_4 represents one or more substituents selected from the list consisting of hydrogen, fluoro, chloro, bromo, methyl and methoxy.

8. A compound according to any of claims 1-7, wherein, R_4 represents 4-chloro.

9. A compound according to any of claims 1-8, wherein R_5 and R_6 each independently represent hydrogen or $(C_1$-$C_6)$alkyl.

10. A compound according to any of claims 1-9, wherein R_5 or R_6 each independently represents hydrogen, $(C_1$-$C_4)$alkyl or methyl.

11. A compound according to any of claims 1-10, wherein R_7 represents $(C_1$-$C_{10})$alkyl, $(C_3$-$C_6)$cyclic hydrocarbon group, $(C_2$-$C_{10})$olefinic group, heterocyclyl,

$(C_2$-$C_{10})$alkynyl, $(C_1$-$C_{10})$alkyl-heterocyclyl, $(C_1$-$C_{10})$alkyl-$(C_3$-$C_6)$cyclic hydrocarbon group, $(C_2$-$C_{10})$olefinic group-heterocyclyl, $(C_2$-$C_{10})$, olefinic group-$(C_3$-$C_6)$cyclic hydrocarbon group, $(C_2$-$C_{10})$alkynyl-heterocyclyl, $(C_2$-$C_{10})$alkynyl-$(C_3$-$C_6)$cyclic hydrocarbon group; and wherein R_7 may optionally be substituted by one or more substituents represented by R_8.

12. A compound according to any of claims 1-11, wherein R_7 represents $(C_1$-$C_6)$alkyl, $(C_3$-$C_6)$cyclic hydrocarbon group, $(C_2$-$C_6)$olefinic group, heterocyclyl, $(C_2$-$C_6)$alkynyl, $(C_1$-$C_6)$alkyl-heterocyclyl, $(C_1$-$C_6)$alkyl-$(C_3$-$C_6)$cyclic hydrocarbon group, $(C_2$-$C_6)$olefinic group-heterocyclyl, $(C_2$-$C_6)$, olefinic group-$(C_3$-$C_6)$cyclic hydrocarbon group, $(C_2$-$C_6)$alkynyl-heterocyclyl, $(C_2$-$C_6)$alkynyl-$(C_3$-$C_6)$cyclic hydrocarbon group; and wherein R_7 may optionally be substituted by one or more substituents represented by R_8.

13. A compound according to any of claism 1-12, wherein R_7 represents methyl, ethyl, propyl, iso-propyl, butyl, tert-butyl, pentyl, heptyl, nonyl, 2-methyl-propyl, 1-methyl-propyl, 2,2-dimethyl-propyl, cyclopropyl, cyclobutyl, phenyl, ethenyl, propenyl, phenylmethyl, phenyl-1-allyl or 2-, 3- or 4- pyridyl, all of which may be substituted by R_8.

14. A compound according to any of claims 1-13, wherein R_8 represents halogen, hydroxy, trifluoromethyl, amino, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, $(C_1$-$C_6)$alkylamino, $(C_1$-$C_6)$alkoxycarbonyl, $(C_1$-$C_9)$trialkylammonium in association with a pharmaceutically acceptable anion, cyano, COOH or Y-R_9.

15. A compound according to any of claims 1-14, wherein R_8 represents hydroxyl or carboxy.

16. A compound according to any of claims 1-5, wherein Y represents -O-, -NR_a-, -NR_aC(O)-, -C(O)NR_a-, -C(O)-, -C(O)O-, -OC(O)-, -NR_aC(O)O- or -$O(CH_2CH_2O)_n$- wherein n is 1, 2, 3 or 4, and R_a and R_b both represents hydrogen.

17. A compound according to any of claims 1-16, wherein Y represents –C(O)-O-, NH-C(O)-O-, -O-, -O-C(O)- or -O(CH_2CH_2O)$_n$- wherein n is 3.

18. A compound according to any of claims 1-17, wherein R_9 represents (C_1-C_4)alkyl, (C_2-C_3)olefinic group, (C_3-C_6)cyclic hydrocarbon group, heterocyclyl, (C_2-C_3)alkynyl, (C_1-C_3)alkyl-(C_3-C_6)cyclic hydrocarbon or (C_1-C_3)alkyl-heterocyclyl, wherein R_9 may optionally be substituted by one or more substituents represented by R_{10}.

19. A compound according to any of claims 1-18, wherein R_9 represents (C_1-C_4)alkyl or (C_1-C_3)alkyl-(C_3-C_6)cyclic hydrocarbon.

20. A compound according to any of claims 1-19, wherein R_9 represents methyl, ethyl, tert-butyl or phenylmethyl.

21. A compound according to any of claims 1-20, wherein R_{10} represents fluoro, chloro, hydroxy, trifluoromethyl, amino, (C_1-C_3)alkyl, (C_1-C_3)alkoxy, (C_1-C_3)alkylamino or (C_1-C_3)alkoxycarbonyl.

22. A compound according to claim 1, wherein R_1 is methyl; R_2 is 2-chloro; R_3 is 2-methyl and 4-fluoro, or 2-methyl and 4-bromo; R_4 is hydrogen or 4-chloro;
R_5 and R_6 independently represent hydrogen or (C_1-C_4)alkyl;
R_7 represents (C_1-C_{10})alkyl, (C_3-C_6)cyclic hydrocarbon group, (C_2-C_{10})olefinic group, heterocyclyl, (C_2-C_{10})alkynyl, (C_1-C_{10})alkyl-heterocyclyl, (C_1-C_{10})alkyl-(C_3-C_6)cyclic hydrocarbon group, (C_2-C_{10})olefinic group-heterocyclyl, (C_2-C_{10}), olefinic group-(C_3-C_6)cyclic hydrocarbon group, (C_2-C_{10})alkynyl-heterocyclyl, (C_2-C_{10})alkynyl-(C_3-C_6)cyclic hydrocarbon group; and wherein R_7 may optionally be substituted by one or more substituents represented by R_8;
R_8 represents halogen, hydroxy, trifluoromethyl, amino, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, (C_1-C_6)alkylamino, (C_1-C_6)alkoxycarbonyl, (C_1-C_9)trialkylammonium in association with a pharmaceutically acceptable anion, cyano, -COOH or Y-R_9;
Y represents –O-, -NR_a-, -NR_aC(O)-, -C(O)NR_a-, -C(O)-, -C(O)O-, -OC(O)-, -NR_aC(O)O- or -O(CH_2CH_2O)$_n$- wherein n is 1, 2, 3 or 4, and R_a and R_b both represents hydrogen;

R_9 represents $(C_1\text{-}C_3)$alkyl, $(C_2\text{-}C_3)$olefinic group, $(C_3\text{-}C_6)$cyclic hydrocarbon group, heterocyclyl, $(C_2\text{-}C_3)$alkynyl, $(C_1\text{-}C_3)$alkyl-$(C_3\text{-}C_6)$cyclic hydrocarbon or $(C_1\text{-}C_3)$alkyl-heterocyclyl, wherein R_9 may optionally be substituted by one or more substituents represented by R_{10};

R_{10} represents fluoro, chloro, hydroxy, trifluoromethyl, amino, $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, $(C_1\text{-}C_3)$alkylamino or $(C_1\text{-}C_3)$alkoxycarbonyl;

and pharmaceutically acceptable salts solvates or hydrates thereof.

23. A compound according to claim 1, wherein R_1 is methyl; R_2 is 2-chloro; R_3 is 2-methyl and 4-fluoro, or 2-methyl and 4-bromo; R_4 is hydrogen or 4-chloro;

R_5 and R_6 independently represent hydrogen or $(C_1\text{-}C_4)$alkyl;

R_7 represents $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cyclic hydrocarbon group, $(C_2\text{-}C_6)$olefinic group, heterocyclyl, $(C_2\text{-}C_6)$alkynyl, $(C_1\text{-}C_6)$alkyl-heterocyclyl, $(C_1\text{-}C_6)$alkyl-$(C_3\text{-}C_6)$cyclic hydrocarbon group, $(C_2\text{-}C_6)$olefinic group-heterocyclyl, $(C_2\text{-}C_6)$, olefinic group-$(C_3\text{-}C_6)$cyclic hydrocarbon group, $(C_2\text{-}C_6)$alkynyl-heterocyclyl, $(C_2\text{-}C_6)$alkynyl-$(C_3\text{-}C_6)$cyclic hydrocarbon group; and wherein R_7 may optionally be substituted by one or more substituents represented by R_8;

R_8 represents halogen, hydroxy, trifluoromethyl, amino, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $(C_1\text{-}C_6)$alkylamino, $(C_1\text{-}C_6)$alkoxycarbonyl, $(C_1\text{-}C_9)$trialkylammonium in association with a pharmaceutically acceptable anion, cyano, -COOH or Y-R_9;

Y represents –O-, -NR_a-, -NR_aC(O)-, -C(O)NR_a-, -C(O)-, -C(O)O-, -OC(O)-, -NR_aC(O)O- or -$O(CH_2CH_2O)_n$- wherein n is 1, 2, 3 or 4, and R_a and R_b both represents hydrogen;

R_9 represents $(C_1\text{-}C_3)$alkyl, $(C_2\text{-}C_3)$olefinic group, $(C_3\text{-}C_6)$cyclic hydrocarbon group, heterocyclyl, $(C_2\text{-}C_3)$alkynyl, $(C_1\text{-}C_3)$alkyl-$(C_3\text{-}C_6)$cyclic hydrocarbon or $(C_1\text{-}C_3)$alkyl-heterocyclyl, wherein R_9 may optionally be substituted by one or more substituents represented by R_{10};

R_{10} represents fluoro, chloro, hydroxy, trifluoromethyl, amino, $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, $(C_1\text{-}C_3)$alkylamino or $(C_1\text{-}C_3)$alkoxycarbonyl;

and pharmaceutically acceptable salts solvates or hydrates thereof.

24. A compound according to claim 1, wherein R_1 is methyl; R_2 is 2-chloro; R_3 is 2-methyl and 4-fluoro, or 2-methyl and 4-bromo; R_4 is hydrogen or 4-chloro;

R_5 and R_6 independently represent hydrogen or methyl;

R_7 represents methyl, ethyl, propyl, iso-propyl, butyl, tert-butyl, pentyl, heptyl, nonyl, 2-methyl-propyl, 1-methyl-propyl, 2,2-dimethyl-propyl, cyclopropyl, cyclobutyl, phenyl, ethenyl, propenyl, phenylmethyl, phenyl-1-allyl or 2-, 3- or 4- pyridyl, all of which may be substituted by R_8;

R_8 represents hydroxyl, carboxy;

Y represents –C(O)-O-, , NH-C(O)-O, -O-, -O-C(O)- or $-O(CH_2-CH_2-O)_n-$, n being 3;

R_9 represents methyl, ethyl, tert-butyl or phenylmethyl;

R_{10} represents fluoro, chloro, hydroxy, trifluoromethyl, amino, (C_1-C_3)alkyl, (C_1-C_3)alkoxy, (C_1-C_3)alkylamino or (C_1-C_3)alkoxycarbonyl;

and pharmaceutically acceptable salts, solvates and hydrates thereof.

25. A compound according to claim 1 selected from the group consisting of

Succinic acid benzyl ester 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Succinic acid mono-{1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl} ester;

Sodium 3-{1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethoxycarbonyl}-propionate;

{2-[2-(2-Methoxy-ethoxy)-ethoxy]-ethoxy}-acetic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

{2-[2-(2-Methoxy-ethoxy)-ethoxy]-ethoxy}-acetic acid 1-{(4-bromo-2-methyl-phenyl)-[3-chloro-4-(2-methyl-benzoyl)-phenyl]-carbamoyloxy}-ethyl ester;

Succinic acid benzyl ester 1-{(4-bromo-2-methyl-phenyl)-[3-chloro-4-(2-methyl-benzoyl)-phenyl]-carbamoyloxy}-ethyl ester;

Succinic acid mono-(1-{(4-bromo-2-methyl-phenyl)-[3-chloro-4-(2-methyl-benzoyl)-phenyl]-carbamoyloxy}-ethyl) ester;

Succinic acid {(4-bromo-2-methyl-phenyl)-[3-chloro-4-(2-methyl-benzoyl)-phenyl]-carbamoyloxy}-methyl ester methyl ester;

Succinic acid benzyl ester {(4-bromo-2-methyl-phenyl)-[3-chloro-4-(2-methyl-benzoyl)-phenyl]-carbamoyloxy}-methyl ester;

Acetic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Propionic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Butyric acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Butyric acid [[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-methyl ester;

Pentanoic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Hexanoic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Octanoic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Decanoic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Succinic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester ethyl ester;

Methoxy-acetic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Methoxy-acetic acid [[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-methyl ester;

Butyric acid 1-[[3-chloro-4-(4-chloro-2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

3-Methoxy-propionic acid 1-[[3-chloro-4-(4-chloro-2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

3,3-Dimethyl-butyric acid [[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-methyl ester;

Cyclopropanecarboxylic acid [[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-methyl ester;

Cyclobutanecarboxylic acid [[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-methyl ester;

2-Hydroxy-propionic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

2-Methyl-but-2-enoic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

2-Hydroxy-2-methyl-propionic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

2-Hydroxy-2-methyl-propionic acid 1-[[3-chloro-4-(4-chloro-2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Isobutyric acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Isobutyric acid [[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-methyl ester;

2,2-Dimethyl-propionic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

3-Methyl-butyric acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

2-Methyl-butyric acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Cyclopropanecarboxylic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Acrylic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

But-2-enoic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

But-2-enoic acid [[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-methyl ester;

Cyclobutanecarboxylic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

3-Methoxy-propionic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

2-Acetoxy-propionic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

2,2-Dimethyl-propionic acid [[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-methyl ester;

3-Phenyl-acrylic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Benzoic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Pyridine-2-carboxylic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Isonicotinic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Nicotinic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Nicotinic acid 1-[[3-chloro-4-(4-chloro-2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

2-Hydroxy-benzoic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

Hydroxy-phenyl-acetic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester;

(S)-2-tert-Butoxycarbonylamino-3-hydroxy-propionic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester (diastereomer A); and

(S)-2-tert-Butoxycarbonylamino-3-hydroxy-propionic acid 1-[[3-chloro-4-(2-methyl-benzoyl)-phenyl]-(4-fluoro-2-methyl-phenyl)-carbamoyloxy]-ethyl ester (diastereomer B).

26. A compound according to any of claims 1-25 for use in therapy.

27. A pharmaceutical composition comprising a compound according to any of claims 1-25, optionally together with another therapeutically active compound, and one or more pharmaceutically acceptable carriers or excipients.

28. A formulation according to claim 27, wherein said other therapeutically active compound is selected from the list consisting of glucocorticoids, vitamin D analogues, anti-histamines, platelet activating factor (PAF) antagonists, anticolinergic agents, methyl xanthines, β-adrenergic agents, COX-2 inhibitors, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillaminé, serum cholesterol-reducing agents, retinoids, zinc salts, and salicylazosulfapyridin (Salazopyrin).

29. A method for the treatment of acne, atopic dermatitis, contact dermatitis, psoriasis, asthma, allergy, arthritis, rheumatoid arthritis, spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease, uveitis and septic shock, the method comprising administering to a patient in need thereof an effective amount of a compound according to any of claims 1-25, optionally in combination with another therapeutically active compound.

30. A method according to claim 29, wherein said other therapeutically active compound is selected from the list consisting of glucocorticoids, vitamin D analogues, anti-histamines, platelet activating factor (PAF) antagonists, anticolinergic agents, methyl xanthines, β-adrenergic agents, COX-2 inhibitors, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillamine, serum cholesterol-reducing agents, retinoids, zinc salts, and salicylazosulfapyridin (Salazopyrin).

31. The use of a compound according to any of claims 1-25 in the manufacture of a medicament for the treatment of acne, atopic dermatitis, contact dermatitis, psoriasis, asthma, allergy, arthritis, rheumatoid arthritis, spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease, uveitis or septic shock.